54045-76-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5-thiazolecarboxylic acid is used as a reagent for the synthesis of azole-based protein kinase B inhibitors. These inhibitors have potential anti-cancer properties, making them valuable in the development of new cancer treatments. 2-Bromo-5-thiazolecarboxylic acid's ability to contribute to the creation of these inhibitors highlights its importance in the pharmaceutical industry, particularly in the ongoing search for effective cancer therapies.

InChI:InChI=1/C4H2BrNO2S/c5-4-6-1-2(9-4)3(7)8/h1H,(H,7,8)/p-1

Upstream product

• 41731-83-3 ethyl 2-bromo-1,3-thiazole-5-carboxylate 
• 54045-74-8 methyl 2-bromo-1,3-thiazole-5-carboxylate 

Downstream Products

• 857982-30-0 2-Oxo-2,3-dihydrothiazole-5-carboxylic acid 
• 148637-74-5 2-chloro-1,3-thiazole-5-carbonyl chloride 
• 1029088-60-5 2-bromo-N-(5-(4-p-tolylthiazol-2-ylcarbamoyl)thiazol-2-yl)thiazole-5-carboxamide 
• 1029087-45-3 2-bromo-N-(5-p-tolylthiazol-2-yl)thiazole-5-carboxamide 
• 1029087-60-2 tert-butyl 3-(2-bromothiazole-5-carboxamido)-5-(4-fluorophenyl)-1H-pyrazole-1-carboxylate 
• 1094070-77-5 (2-bromo-thiazol-5-yl)-carbamic acid tert-butyl ester 
• 1258291-88-1 2-bromo-N-(4-(2,6-dichlorobenzamido)pyridin-2-yl)thiazole-5-carboxamide 
• 1209458-80-9 2-bromo-5-(trifluoromethyl)-1,3-thiazole 
• 941716-91-2 2-(pyrrolidin-1-yl)thiazole-5-carboxylic acid 

Relevant academic research and scientific papers

FLUOROALKYL-OXADIAZOLES AND USES THEREOF

Provided herein are compounds identified as inhibitors of HDAC6 activity that can be used to treat various diseases and disorders.

NOVEL COMPOUND EXHIBITING ENTEROPEPTIDASE INHIBITORY ACTIVITY

The present invention relates to a novel compound exhibiting enteropeptidase-inhibiting activity, a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing and treating metabolic diseases such as obesity, diabetes mellitus or

SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X, Y, A, G, R1, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

CD16A BINDING AGENTS AND USES THEREOF

Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.

SUBSTITUTED NITROGEN CONTAINING COMPOUNDS

Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

HETEROARLY AMIDES AS INHIBITORS OF PROTEIN AGGREGATION

The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy body disease, Parkinson's disease with dementia, fronto-temporal dementia, Huntington's Disease, amyotrophic lateral sclerosis, and multiple system atrophy, and cancer and melanoma.

2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME

The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I): wherein R1, R2 and X are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods of using same.

HETEROCYCLIC MODULATORS OF PKB

The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein Formula (I). The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

5,6,7,8-tetrahydropyrido[2,3-D]pyrimidines

PCT No. PCT/US96/14822 Sec. 371 Date Feb. 26, 1999 Sec. 102(e) Date Feb. 26, 1999 PCT Filed Sep. 17, 1996 PCT Pub. No. WO97/41115 PCT Pub. Date Nov. 6, 1997Glutamic acid derivatives in which the amino group is substituted with a 2-amino-5,6,7,8-tetrahydro